Inclusion Criteria:

- There are two groups of patients eligible for this study; treatment group 1 consists
of patients with extremity sarcomas other than potentially curable osteosarcoma or
Ewing's sarcoma who are candidates for potentially curative surgery; treatment group
2 consists of patients with metastatic or inoperable sarcoma, for which there is no
known curative or survival prolonging palliative therapy, or failure of these
therapies; patients must have at least one site of measurable disease by radiologic
imaging techniques; patients must have at least one palpable tumor mass with no
overlying viscera which is amenable to biopsy; the tumor mass should be approximately
2 cm or greater in diameter; patients with smaller palpable tumors are eligible if
participation is approved by the treating surgeon after discussion with the study
chairperson

- As of 5/30/07, no subjects will accrue to Treatment Group I

- Life expectancy >= 2 months

- ECOG performance status =< 2

- Pretreatment laboratory data, obtained within 14 days of study entry, must meet the
following criteria:

- ANC >= 1,500/mm^3

- Platelets >= 100,000/mm^3

- SGOT =< 2.5-times the upper limit of normal (ULN)

- SGPT =< 2.5-times ULN

- Total Bilirubin =< ULN

- Serum creatinine =< 1.5-times ULN

- >= 3 weeks since major surgery unrelated to study disease (sarcoma)

- >= 3 weeks since chemotherapy or radiation therapy (6 weeks for nitrosourea or
mitomycin C chemotherapy)

- No prior treatment with sorafenib (BAY 43-9006) or specific inhibitors of MAPK kinase
pathways are permitted; a previously irradiated tumor site cannot be used for
clinical or correlative measurements, although irradiation to sites other than a
measurable site is permitted; there are no limitations on the extent or type of prior
therapy received by the patient other than the time intervals indicated in the above
and demonstrating complete recovery from any adverse effects associated by satisfying
all relevant eligibility criteria

- Patients who are on warfarin anticoagulation are allowed to participate as long as
they are converted to a low molecular weight heparin (e.g. lovenox) from study entry
until at least day 56

- Women of childbearing potential must not be pregnant or lactating; all women of
childbearing potential (age < 50, LMP < 12 months ago) must have a negative serum or
urine pregnancy test (minimum sensitivity 25 IU/L of beta-HCG) within 72 hr prior to
receiving the study medication; BAY43-9006 has antiproliferative effects, which may
be harmful to the developing fetus or nursing infant

- Fertile males and females must use adequate contraception

- Signed informed consent

Exclusion Criteria:

- Ewing's sarcoma or osteosarcoma that is potentially curable with surgery,
chemotherapy, and/or radiation therapy

- Active brain metastases including evidence of cerebral edema by CT scan or MRI, or
progression from prior imaging study, any requirements for steroids, or
enzyme-inducing anti-convulsant agents, or clinical symptoms of/from brain
metastases; patients with treated and/or stable brain metastasis who are asymptomatic
can be enrolled, if otherwise eligible

- Any uncontrolled serious medical or psychiatric illness; particular note is given to
uncontrolled hypertension (discretion left to investigators) and significant
proteinuria > 1 gm/24 hr (does not require quantitation in absence of clinical
indication)

- Patients receiving other investigational agents

- HIV patients receiving combination anti-retroviral therapy are excluded because of
potential pharmacokinetic interactions